Phenobarbitone-associated Pediatric Dress Syndrome Complicated by Secondary Hemophagocytic Lymphohistiocytosis: A Case Report with Literature Review
SN Comprehensive Clinical Medicine · 05.11.2026 · 8 (1)
DOI: 10.1007/s42399-026-02860-4 ↗Kurz gefasst
Fallbericht in der Zeitschrift SN Comprehensive Clinical Medicine, online erschienen am 05.11.2026. Verfasst von Nikita Jakhar und 8 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben.
Abstract (Originalsprache)
Introduction
Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe T-cell-mediated drug hypersensitivity reaction with delayed onset, multisystem involvement, and significant morbidity. Most patients improve after withdrawal of the offending drug and initiation of immunomodulatory therapy, but a minority of patients progress to secondary hemophagocytic lymphohistiocytosis (HLH), a life-threatening hyperinflammatory syndrome with high mortality without early recognition. DRESS and HLH may coexist in children, but such a situation is uncommon, and they represent a significant diagnostic challenge because of overlapping clinical and laboratory findings. Case Presentation We describe a previously healthy 4-year-old boy who developed fever, diffuse erythematous rash, facial oedema, eosinophilia, hepatitis, and lymphadenopathy approximately 4 weeks after initiation of concomitant valproate and phenobarbitone, with phenobarbitone considered the suspected principal culprit, fulfilling the RegiSCAR criteria for definite DRESS syndrome. Despite withdrawal of the suspected drugs and treatment with intravenous immunoglobulin, fever persisted and systemic inflammation progressed, despite gradual improvement in cutaneous manifestations. Neurological abnormalities were also observed during the evolving illness. Serial evaluation subsequently established secondary HLH, with progressive bicytopenia, hyperferritinaemia (> 1000 µg/L), hypertriglyceridaemia, hypofibrinogenaemia, and bone marrow haemophagocytosis. Escalation to HLH-directed therapy with dexamethasone and etoposide resulted in progressive clinical and laboratory recovery with complete remission at six-month follow-up.
Conclusions
This case highlights the diagnostic challenge of secondary HLH in pediatric DRESS syndrome, particularly when cutaneous manifestations improve despite persistent systemic inflammation. Neurological deterioration accompanied the evolving illness, but its temporal relationship to the onset of HLH remains uncertain. Persistent fever, evolving cytopenias, and worsening inflammatory parameters should prompt reassessment for secondary HLH, even when cutaneous manifestations appear to improve.
Zitieren
APA
Jakhar, N., Goel, N., Sharma, S., Mehndiratta, S., Chopra, N., Ghasi, R. G., Rishi, B., Misra, A., & Singh, A. (2026). Phenobarbitone-associated Pediatric Dress Syndrome Complicated by Secondary Hemophagocytic Lymphohistiocytosis: A Case Report with Literature Review. SN Comprehensive Clinical Medicine, 8(1). https://doi.org/10.1007/s42399-026-02860-4
Vancouver
Jakhar N, Goel N, Sharma S, Mehndiratta S, Chopra N, Ghasi RG, et al. Phenobarbitone-associated Pediatric Dress Syndrome Complicated by Secondary Hemophagocytic Lymphohistiocytosis: A Case Report with Literature Review. SN Comprehensive Clinical Medicine. 2026;8(1). doi:10.1007/s42399-026-02860-4
BibTeX
@article{Jakhar2026,
author = {Jakhar, Nikita and Goel, Neha and Sharma, Saurav and Mehndiratta, Sumit and Chopra, Nidhi and Ghasi, Rohini Gupta and Rishi, Bhavika and Misra, Aroonima and Singh, Amitabh},
title = {Phenobarbitone-associated Pediatric Dress Syndrome Complicated by Secondary Hemophagocytic Lymphohistiocytosis: A Case Report with Literature Review},
journal = {SN Comprehensive Clinical Medicine},
year = {2026},
volume = {8},
number = {1},
doi = {10.1007/s42399-026-02860-4}
}
EUVIMED